Cover Image

3D Printing & Pharmaceutical Manufacturing: Opportunities and Challenges

Bhusnure O. G.*, Gholve V. S., Sugave B. K., Dongre R. C., Gore S. A., Giram P. S.

Abstract


Many researchers have attempted to use computer-aided design (C.A.D) and computer-aided manufacturing (CAM) to realize a scaffold that provides a three-dimensional (3D) environment for regeneration of tissues and organs. As a result, several 3D printing technologies, including stereolithography, deposition modeling, inkjet-based printing and selective laser sintering have been developed. Because these 3D printing technologies use computers for design and fabrication, and they can fabricate 3D scaffolds as designed; as a consequence, they can be standardized. Growth of target tissues and organs requires the presence of appropriate growth factors, so fabrication of 3Dscaffold systems that release these biomolecules has been explored. A drug delivery system (D.D.S) that administrates a pharmaceutical compound to achieve a therapeutic effect in cells, animals and humans is a key technology that delivers biomolecules without side effects caused by excessive doses. 3D printing technologies and D. D. Ss have been assembled successfully, so new possibilities for improved tissue regeneration have been suggested. If the interaction between cells and scaffold system with biomolecules can be understood and controlled, and if an optimal 3D tissue regenerating environment is realized, 3D printing technologies will become an important aspect of tissue engineering research in the near future. 3D Printing promises to produce complex biomedical devices according to computer design using patient-specific anatomical data. Since its initial use as pre-surgical visualization models and tooling molds, 3D Printing has slowly evolved to create one-of-a-kind devices, implants, scaffolds for tissue engineering, diagnostic platforms, and drug delivery systems. Fuelled by the recent explosion in public interest and access to affordable printers, there is renewed interest to combine stem cells with custom 3D scaffolds for personalized regenerative medicine. Before 3D Printing can be used routinely for the regeneration of complex tissues (e.g. bone, cartilage, muscles, vessels, nerves in the craniomaxillofacial complex), and complex organs with intricate 3D microarchitecture (e.g. liver, lymphoid organs), several technological limitations must be addressed. Until recently, tablet designs had been restricted to the relatively small number of shapes that are easily achievable using traditional manufacturing methods. As 3D printing capabilities develop further, safety and regulatory concerns are addressed and the cost of the technology falls, contract manufacturers and pharmaceutical companies that experiment with these 3D printing innovations are likely to gain a competitive edge. This review compose the basics, types & techniques used, advantages and disadvantages of 3D printing


Keywords


3D Printing; Drug Delivery System; US-FDA Sprit am; 3D Tissue Regeneration

Full Text:

PDF

References


SPRITAM [package insert]. East Windsor, N. J. Aprecia Pharmaceuticals Company 2015. Data on file. Aprecia Pharmaceuticals Company.

Centers for Disease Control and Prevention. Epilepsy Fast Facts. March 12, 2015. Available: http://www.cdc.gov/epilepsy/basics/fast-facts.htm. Accessed July 29, 2015.

Chen P. H, et al., Prevalence of Perceived Dysphagia and Quality-of-Life Impairment in a Geriatric Population. Dysphagia. 2009; 24(1):1-6.

Ekberg O. et al., Social and psychological burden of dysphagia; its impact on diagnosis and treatment. Dysphagia. 2002; 17:139-146.

Davis K. L, Candrilli S. D, Edin H. M. Prevalence and Cost of Nonadherence with Antiepileptic Drugs in an Adult Managed Care Population. Epilepsia. 2008. 49.

Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. International Journal of Pharmaceutics. 430 (2012) 197-206.

Cramer J. A, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy and Behavior. 08/2002; 3(4):338-342.




DOI: http://dx.doi.org/10.21746/ijbio.2016.01.006

Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.